Regorafenib Delays Progression in Advanced Osteosarcoma

Treatment options for patients with metastatic osteosarcoma who progress on first-line chemotherapy are limited, and prognosis for these patients is extremely poor. The activity of second-line chemotherapy in osteosarcoma is marginal, and treatment with checkpoint inhibitors, unfortunately, also appears ineffective. More promising results were reported with targeted therapy, in particular with agents targeting angiogenesis and […]

Read More

Shortened Survival With Minimally Invasive Surgery for Cervical Cancer

Treatment for patients with early-stage cervical cancer most often includes radical hysterectomy, which is associated with cure in more than 80% of patients. In recent years, minimally invasive surgery (laparoscopic or robotic) has largely replaced laparotomy (open abdominal surgery) as the preferred surgical method due to a decrease surgical morbidity associated with less invasive procedures. […]

Read More

osimertinib-nsclc-primelines

Broad Activity of Lorlatinib in ALK-Positive Advanced NSCLC

About 3% to 5% of patients with advanced non-small cell lung cancer (NSCLC) harbor ALK rearrangements. For many years, crizotinib was the only first-line treatment choice for these patients. However, in recent years several second-generation ALK inhibitors, including alectinib, ceritinib and brigatinib, have shown better efficacy than crizotinib, particularly for patients with brain metastases, and […]

Read More

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer

Immunotherapy with PD-1 and PD-L1 inhibitors has become the standard of care for patients with advanced urothelial cancer who have progressed on or are ineligible for cisplatin-based therapy. The success of these agents in the metastatic setting has led to investigation in earlier stages of disease. For muscle-invasive bladder cancer (MIBC), the current standard of […]

Read More

Cisplatin Chemoradiation Remains Gold Standard for Low-Risk HPV+ SCCHN

The incidence of human papilloma virus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is increasing. Oropharyngeal squamous cell carcinoma is considered a distinctive disease from HPV-negative cancer and has a better prognosis. Currently, the treatment of oropharyngeal cancer without distant metastases is similar for both HPV-positive and HPV-negative disease, with concomitant cisplatin-based […]

Read More

liquid-biopsy-nsclc-primelines

Utility of Liquid Biopsy for Mutation Detection in NSCLC

In non-small lung cancer (NSCLC), genetic alterations in genes such as EGFR, ALK, ROS1, and BRAF have been validated as reliable targets, and molecular testing and genotype-driven targeted therapy is the standard of care for patients with advanced NSCLC harboring these alterations. However, tumor tissue may be difficult to obtain or yield inadequate samples to […]

Read More

Lurbinectedin Active in BRCA1/2-Mutated Advanced Breast Cancer

Patients with advanced breast cancer who carry germline mutations in BRCA1/2 genes are highly sensitive to DNA damage due to deficiencies in homologous recombination repair (HRR) mechanisms. Lurbinectedin, an analog of the DNA damaging agent trabectedin, is a selective inhibitor of the transcription of protein-coding genes that results in accumulation of double-strand DNA breaks. In […]

Read More

Three Articles Worth Reading

ASCO Guidelines on HPV Testing in Head and Neck Cancer. The American Society for Clinical Oncology (ASCO) released a guideline endorsement for the College of American Pathologists guidelines surrounding human papillomavirus (HPV) testing in patients with head and neck cancers. The new guidelines call for HPV testing for all newly diagnosed squamous cell oropharyngeal cancers […]

Read More

Fatal Toxicity Associated With Immune Checkpoint Inhibitors

Immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have become an essential component of cancer treatment, and in many tumors, are now considered the standard of care. Because of their mechanism of action, these agents are associated with a unique adverse event (AE) profile driven by immunologic activation. While most immune related adverse events […]

Read More

Early Evidence of Activity of Trabectedin and Olaparib in Sarcoma

Bone and soft tissue sarcomas comprise a group of biologically diverse tumors that are associated with poor prognosis, despite an increasing number of treatment options that include chemotherapy and targeted therapy. Trabectedin is a safe and effective second-line therapy approved for treatment of advanced soft tissue sarcoma (STS). Poly(ADP ribose) polymerase (PARP) inhibitors are a […]

Read More